This Month in Psychopharmacology

FDA Rejects NDA for ADHD Medication "Dasotraline"

In disappointing news, the FDA has decided not to approve Sunovion's dasotraline, a dual dopamine and norepinephrine reuptake inhibitor, for the treatment of attention deficit-hyperactivity disorder (ADHD). Although dasotraline has been tested in several placebo-controlled short-term and long-term studies, the FDA suggests that additional data on the safety and efficacy of dasotraline are needed. Dasotraline is also being studied as a potential treatment for binge eating disorder, with expected FDA submission sometime in 2018.

More information



For more information on ADHD:

This Month in Psychopharmacology: ADHD